SOUTH SAN FRANCISCO, CA--(Marketwire - October 31, 2007) - Cytokinetics, Incorporated (NASDAQ: CYTK) reported revenues from research and development collaborations of $4.1 million for the third quarter of 2007. Net loss for the third quarter of 2007 was $11.3 million, or $0.24 per share. As of September 30, 2007, cash, cash equivalents, restricted cash and marketable securities totaled $158.1 million.
